|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Fasturtec powd for inj[法舒克 乾粉注射劑] information |
|
|
|
製造商 |
Sanofi-aventis |
|
代理/經銷商 |
Sanofi-aventis |
|
成份 |
Rasburicase |
|
適應症 |
Treatment & prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in patients with haematologic malignancy with a high tumor burden & at risk of a rapid tumor lysis or shrinkage at initiation of chemotherapy. |
|
用量 |
0.2 mg/kg/day as a once daily 30-min IV infusion for 5-7 days. |
|
過量 |
View Fasturtec[法舒克] overdosage for action to be taken in the event of an overdose. |
|
美國食品藥物管理局之懷孕等級 |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
禁忌 |
G6PD deficiency & other cellular metabolic disorders known to cause haemolytic anaemia. |
|
注意事項 |
Monitor closely for onset of allergic-type undesirable effects, especially allergic skin reaction or bronchospasm. History of atopic allergies. Pregnancy & lactation. |
|
不良反應 |
Fever, vomiting, nausea. Uncommonly, diarrhoea, headache, allergic reactions including bronchospasm.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
[Click for Fasturtec[法舒克] detailed prescribing infomation]
View more drug interactions with Fasturtec[法舒克] |
|
使用上注意 |
For caution against possible variation of physical aspect of medicine... click to view Fasturtec[法舒克] detailed prescribing infomation |
|
儲存 |
View Fasturtec[法舒克] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Fasturtec[法舒克] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Fasturtec[法舒克] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
|
|
Manufacturer: |
Sanofi-aventis |
|
Distributor: |
Sanofi-aventis |
|
|
|
|
